General Proximity

Executive Summary

General Proximity is a San Francisco-based biotechnology company pioneering a generalized platform for induced proximity to control biological processes and drug previously undruggable targets. Founded in 2021, the company has developed a mechanism-agnostic discovery engine that identifies novel proximity-based therapeutics, with an initial focus on oncology and immunology. By manipulating protein interactions, General Proximity aims to expand the druggable proteome and create a new class of medicines. The platform's versatility could enable rapid expansion into other therapeutic areas, positioning the company as a leader in the emerging field of proximity-based drug discovery. As a private company with no disclosed funding or pipeline details, General Proximity remains in early stages, but its innovative approach has attracted attention from the biopharma industry. Despite the promise of its platform, General Proximity faces significant challenges typical of early-stage biotechs, including the need for substantial capital, rigorous preclinical validation, and eventual clinical proof-of-concept. The company's stage is listed as 'Approved,' which may indicate a formal approval for its technology or business structure, but no revenue or partnered programs are evident. Conviction is tempered by the absence of disclosed data or milestones, yet the potential of proximity-based modalities—such as PROTACs and molecular glues—supports a favorable long-term outlook. Success will hinge on execution, attracting top talent, and securing partnerships or financing to advance its platform toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Series A/B Financing Round70% success
• Q2 2027Lead Program Nomination for Oncology Indication60% success
• 2027Major Pharmaceutical Partnership or Licensing Deal50% success